Membranous and cytoplasmic Nectin4 expression and outcomes with enfortumab vedotin plus pembrolizumab in metastatic urothelial carcinoma.
Michal Sternschuss, Karissa Whiting, Cansu Yol, Alyssa Arbuiso et autres
801 Background: Enfortumab vedotin plus pembrolizumab (EV/P) is the standard therapy for metastatic urothelial carcinoma (UC) irrespective of Nectin4 expression. The relevance of membranous (mNectin4) and cytoplasmic (cNectin4) expression remains uncertain. Methods: We retrospectively reviewed an institutional database of patients treated with …
us (code pays fourni par la source)